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ABSTRACT 
 
Introduction 
Septic shock is a life-threatening condition requiring vasopressor agents to support the 
circulatory system. Several agents exist with choice typically guided by the specific clinical 
scenario. We used a network meta-analysis approach to rate the comparative efficacy and 
safety of vasopressors for mortality and arrhythmia incidence in septic shock patients.  
 
Methods 
We performed a comprehensive electronic database search including Medline, Embase, 
Science Citation Index Expanded and the Cochrane database. Randomised trials investigating 
vasopressor agents in septic shock patients and specifically assessing 28 day mortality or 
arrhythmia incidence were included. A Bayesian network meta-analysis was performed using 
Markov chain Monte Carlo methods. 
 
Results 
Thirteen trials of low to moderate risk of bias in which 3,146 patients were randomised were 
included. There was no pairwise evidence to suggest one agent was superior over another for 
mortality. In the network meta-analysis, vasopressin was significantly superior to dopamine (OR 
0.68 [95% CI 0.5 to 0.94]) for mortality. For arrhythmia incidence, standard pairwise meta-
analyses confirmed that dopamine led to a higher incidence of arrhythmias than norepinephrine 
(OR 2.69 [95% CI 2.08 to 3.47]). In the network meta-analysis, there was no evidence of 
superiority of one agent over another. 
 
Conclusions 
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In this network meta-analysis, vasopressin was superior to dopamine for 28 day mortality in 
septic shock. Existing pairwise information supports the use of norepinephrine over dopamine. 
Our findings suggest that dopamine should be avoided in patients with septic shock and that 
other vasopressor agents should continue to be based on existing guidelines and clinical 
judgement of the specific presentation of the patient.   
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INTRODUCTION 
 
Septic shock is a life-threatening condition requiring intense patient monitoring and supportive 
therapy for organ dysfunction.[1] Release of inflammatory mediators leads to widespread 
vasodilatation, capillary leak and reduced systemic vascular resistance. After initial fluid 
resuscitation, vasopressor therapy is required. These agents have their effect by increasing 
vascular resistance, raising mean arterial pressure and maintaining perfusion of critical body 
tissues and organ systems.[2]  
 
The two main classes of drugs used are adrenergic (alpha, beta or combined) agonists and 
vasopressin analogues. Alpha-adrenergic agonists increase vascular tone and blood pressure 
while beta-agonists increase blood flow via inotropic and chronotropic effects. Both classes of 
drugs are associated with risks including reduction of cardiac output and regional blood flow for 
alpha-agonists and myocardial ischaemia with beta-agonists.[2,3] In addition to its action on 
adrenergic receptors, dopamine also acts on dopaminergic receptors which can result in 
unwanted side effects including immunosuppression, renal impairment and increased risk of 
arrhythmias.[2] Vasopressin analogues simulate the action of the anti-diuretic hormone (ADH, 
also known as vasopressin). They have multiple effects, and in health they play a key role in 
retention of water in the distal tubules and collecting ducts leading to an increase in circulating 
volume. In shock states they act as vasoconstrictors. Despite short term increase in blood-
pressure in observational studies, there have been concerns that infusion may reduce blood 
flow to the heart, kidneys and intestine.[4] 
 
The latest guidance from the Surviving Sepsis Campaign released in 2012 recommends 
norepinephrine as the first choice vasopressor with addition of epinephrine where an additional 
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agent is needed.[5] Dopamine has fallen out of favour due to evidence suggesting an increased 
risk of arrhythmias and higher mortality.[6] This guidance is based mainly on findings from 
meta-analyses published between 2011-12.[6-8] In the intervening time, there has been growing 
interest in vasopressin analogues although their relative place compared to older vasopressors 
has yet to be fully characterised.[9] The current recommendation from the Surviving Sepsis 
Campaign is that vasopressin can be added to norepinephrine to raise mean arterial pressure 
or reduce norepinephrine requirement although sole use of vasopressin is discouraged.[5]  
 
Existing reviews have predominantly assessed only the direct evidence available in pairwise 
comparisons of vasopressors.[6-9] Network meta-analysis or mixed-treatment comparisons 
allow simultaneous comparisons of multiple treatments and may permit the ranking of the 
different treatments relative to other treatments. Network meta-analysis may also provide more 
accurate effect estimates.[10-14] There has been one previous network meta-analysis that 
included many trials assessing mortality but did not specifically look at safety outcomes.[15] The 
aim of this review was to compare the safety and relative efficacy of different vasopressor 
agents on 28 day mortality and arrhythmia incidence in septic shock patients. 
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METHODS 
 
Trial identification, selection and extraction of data 
A comprehensive electronic search was undertaken. The following databases were searched 
from inception to September 2014: MEDLINE, Embase, Science Citation Index Expanded,  
Cochrane Central Register of Controlled Trials, Clinicaltrials.gov and the World Health 
Organization International Clinical Trials Registry Platform (WHO ICTRP) search portal. We 
used MeSH and free-text terms for various forms of the terms ‘septic’, ‘shock’, ‘vasopressors’ 
and individual types of vasopressors in an intentionally broad strategy. The exact search 
strategy is listed in Appendix 1 (available online). Additional articles or abstracts were retrieved 
by ‘related citation’ search and by manually scrutinising the reference list of relevant 
publications. There were no restrictions on language. 
 
Publications were selected for review if they satisfied the following inclusion criteria: randomised 
clinical trial, human adult patients, two or more of the following arms: vasopressor versus 
another type of vasopressor or no active intervention, reported 28 day mortality or arrhythmias. 
Two authors (MN, MM) independently examined all retrieved articles for inclusion. Any 
disagreement over inclusion or exclusion was resolved by consensus. Data were extracted 
using a pre-designed data collection form by two authors (MN, MM) with disagreements 
resolved by consensus. The following data-points were extracted: first author, year of 
publication, inclusion and exclusion criteria, number of patients, baseline patient characteristics 
including average age, gender and severity score, intervention details including drug, dose and 
timing, risk of bias assessment, arrhythmia incidence and 28 day mortality. Authors of original 
trials were contacted by email where reported data was unclear or unavailable. 
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Risk of bias was assessed using the Cochrane Risk of Bias tool.[16] It includes six domains that 
could affect the effect estimates due to systematic error. These are: sequence generation, 
allocation concealment, blinding of participants, healthcare providers and outcome assessors, 
incomplete outcome data, selective reporting, and other potential sources of bias (such as 
funding). Each domain was rated as low, uncertain or high risk of bias. 
 
Statistical analysis 
Network meta-analysis combines direct evidence within trials and indirect evidence across 
trials.[17] Our analysis was based on guidance by the National Institute for Clinical Excellence 
(NICE) Decision Support Unit (DSU). Execution was similar to previous network meta-analysis 
reviews by our lead author such as in the field of liver resection.[18] Each drug or drug 
combination was considered a separate treatment. This corresponds to the full interaction 
model.[19] A network plot was created to ensure that the trials were connected by treatments 
(i.e. there was at least one trial which allowed indirect comparisons of treatments) using 
Stata/SE 12.1 (StataCorp LP). Any trials that were not connected to the network were excluded. 
A Bayesian network meta-analysis using the Markov chain Monte Carlo method in WinBUGS 
1.4.3 was performed in the presence of sufficient clinical homogeneity using the methods 
suggested by NICE DSU.[20-23] Odds ratios (OR) were calculated for the outcomes. The 
treatment contrast (i.e. log odds ratio) for any two treatments ('functional parameters') were 
modelled as a function of comparisons between each individual treatment and an arbitrarily 
selected reference group ('basic parameters').[11] The reference group was norepinephrine 
where possible. The WinBUGS codes utilised in the analysis are presented in Appendix 2 
(available online).  
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Execution of our network analysis was similar to a prior analysis on liver resection by the senior 
author from our group as summarised below.[18] The posterior probabilities (effect estimates or 
values) of the treatment contrast can vary depending upon the initial values with which the 
simulations are started. To control the random error due to choice of initial values, we attempted 
to perform the network analysis for three different sets of initial values (priors) as per the 
guidance from NICE DSU.[20] If the results from the three different priors were similar 
(convergence, checked by Brooks-Gelman-Rubin plot) then reliability of the results could be 
assumed.[24] We ran the models for at least 30,000 simulations for 'burn in' for three different 
chains (sets of initial values). We ran the models for further 30,000 simulations to obtain the 
effect estimates. We then ensured that the results in the three different chains were similar in 
order to control for random error due to choice of priors. Visual inspection of convergence 
obtained after simulations in the burn in was also performed. 
 
Three different models were run for each outcome. The fixed-effect model assumed that the 
treatment effect was the same across all studies. The random-effects consistency model 
assumed that the treatment effect was distributed normally across the studies but assumed that 
the transitivity assumption was satisfied (i.e., the population studied, the definition of outcomes, 
and the methods used were similar across studies and that there was consistency between the 
direct comparison and indirect comparison). The random-effects inconsistency model did not 
assume the transitivity assumption. If the inconsistency model resulted in a better model fit than 
the consistency model, the results of the network meta-analysis could be unreliable and so 
interpretation would require extreme caution. The choice of the model between fixed-effect 
model and random-effects model was based on the model fit as per the guidelines of the NICE 
TSU.[20] The model fit was assessed by deviance residuals and Deviance Information Criteria 
(DIC). [25] The DIC takes into account the model fit and the model complexity. The simpler 
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model was used, i.e., fixed-effect model if the DIC was similar between the fixed-effect model 
and random-effects model. Alternatively, the random-effects model would be used if it resulted 
in a better model fit as indicated by a DIC lower than that of fixed-effect model by at least three. 
The effect estimates of each pairwise comparison and the 95% credible intervals (equivalent to 
95% confidence intervals in a frequentist meta-analysis) were calculated using the formulae for 
calculating the effect estimates in indirect comparisons.[10] Statistical significance was 
accepted as 95% confidence excluding a value of one. 
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RESULTS 
 
Study selection 
Execution of the search strategy yielded 5,854 records from database inception to September 
2014. After excluding duplicates, there were 4,715 records remaining. A total of 4,662 of these 
records were excluded upon review of title and abstract leaving 53 full-text records for 
screening. Thirteen full-text studies were selected for inclusion. Reasons for exclusion of full-
text records are detailed in figure 1.  
 
Study characteristics 
Study and patient characteristics for included studies are presented in table 1. There were a 
total of 13 trials (11 full-text articles and two reports from ongoing studies). A total of 3,146 
patients were included in analyses of 28 day mortality and 2,198 patients were included in 
analyses of arrhythmias. Trial arms were well balanced within trials. The mean age of patients 
ranged from 51 to 73 where reported. The proportion of female patients ranged from 27% to 
54% where reported. The range of severity scores are displayed in table 1. 
 
Study risk of bias 
Risk of bias assessments for included trials are presented in table 2. Sequence generation and 
allocation concealment were generally at low risk of bias with the exception of the trial by Patel 
et al. The same was true for blinding of patients, healthcare providers and outcome assessors. 
Six of the 13 trials were at risk of bias for missing outcome data due to post-randomisation drop 
outs. In all six cases, the proportion of drop outs relative to the total sample size was not felt to 
have meaningfully altered the reported effect estimate. Overall there were 46 reported drop outs 
from a total of 3,192 patients (average 1.4%, range 0 to 6.3% per study where reported). 
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28 day mortality  
Standard pairwise meta-analyses were possible for two combinations. Two studies compared 
norepinephrine versus dopamine. There was no significant difference in mortality (odds ratio 
(OR) 0.83 [95% CI 0.67 to 1.03]) (appendix figure S2). Three studies compared norepinephrine 
with vasopressin analogues. There was no significant difference in mortality (OR 1.13 [95% CI 
0.86 to 1.48]) (appendix figure S3). There was no change in significance when repeating the 
analysis with random-effects models. There was no visual or statistical evidence of 
heterogeneity.  
 
The network plot showing the connection between comparisons (nodes) is presented in 
appendix figure S4. There was good convergence of the values in both the fixed- and random-
effects models and no evidence of inconsistency. There was no major difference between the 
DIC of the fixed- and random-effects models (121.7 and 123.6 respectively) and so the fixed-
effect model was used for analysis. The relative effect estimates between comparisons in the 
fixed effect model are presented in table 3. Vasopressin was superior to dopamine (OR 0.68 
[95% CI 0.5 to 0.94]). There were no statistically significant differences in the remaining 
comparisons. 
 
Arrhythmias 
Standard pairwise meta-analyses were possible for two combinations. Two studies compared 
norepinephrine versus dopamine. There were significantly more arrhythmias in the dopamine 
group compared to norepinephrine (OR 2.69 [95% CI 2.08 to 3.47]) (appendix figure S5). Three 
studies compared norepinephrine with vasopressin analogues. There was no significant 
difference in arrhythmias between the groups (OR 1.36 [95% CI 0.56 to 3.31]) (appendix figure 
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S6). There was no change in significance when repeating the analysis with random-effects 
models. There was evidence of substantial heterogeneity in the vasopressin comparison. 
 
The network plot showing the connection between comparisons (nodes) is presented in 
appendix figure S7. There was good convergence of values in both the fixed- and random-
effects models with no evidence of inconsistency. However, there was a significant difference 
between the DIC of the fixed- and random-effects models (63.9 and 60.3). We therefore opted 
to utilise the random-effects model. The relative effect estimates between comparisons are 
presented in table 4. The relative effect estimates between comparisons are presented in table 
4. There were no statistically significant differences. Most of the confidence intervals were 
extremely wide (the network meta-analysis estimates utilised both direct and indirect 
information). 
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DISCUSSION 
 
Summary 
In this network meta-analysis of trials assessing 28 day mortality of vasopressor agents, we 
found evidence to suggest superiority of vasopressin over dopamine. Our standard pairwise 
meta-analyses showed no significant difference between comparisons for which there was more 
than one trial available (norepinephrine versus dopamine; norepinephrine versus vasopressin 
analogues). Of trials in the network meta-analysis assessing arrhythmia incidence, we found no 
evidence to suggest one vasopressor over another. Standard pairwise analyses suggested 
greater arrhythmias with dopamine compared to norepinephrine. 
 
Comparison to the literature 
There have been several existing pairwise meta-analyses of vasopressor agents and one 
network meta-analysis to date.[6-9,15] Our findings differ from the previous literature on this 
topic in some areas. The most likely reason for the difference relates to our decision to include 
only trials reporting 28 day mortality for assessment of mortality. This excluded trials in which 
exposure to the interventional vasopressor was limited (a matter of hours in the case of many 
trials for which the primary endpoints were haemodynamic variables) or in which the time point 
of mortality measurement was either ambiguously reported or reported only for early time 
points.  
 
De Backer and colleagues assessed both observational and randomised trials and concluded 
that dopamine administration was associated with greater mortality and a higher incidence of 
arrhythmic events.[6] However, they acknowledged that restricting to the two trials that reported 
28 day mortality (also the two largest) resulted in a similar effect estimate size but with 
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confidence intervals crossing one. Our pairwise findings on arrhythmia incidence are in 
agreement with De Backer and colleagues suggesting superiority of norepinephrine over 
dopamine. Serpa Neto and colleagues investigated the effect of vasopressin and terlipressin in 
vasodilatory shock.[9] They concluded that vasopressin significantly reduced mortality, including 
the subset of trials assessing septic shock. However, this conclusion is not completely held up 
by their data which demonstrate non-significant effects when both terlipressin and vasopressin 
individually are compared to norepinephrine (both sets of confidence intervals include one). 
Furthermore, their combined analysis of vasopressin and terlipressin together which does 
demonstrate a significant mortality benefit to vasopressin analogues may be inaccurate due to 
double counting of a control group in a three arm trial by Morelli and colleagues.[26] Adjustment 
to take into account this double counting renders the combined effect estimate non-significant.  
 
A meta-analysis by Vasu et al. of six trials concluded that norepinephrine was superior to 
dopamine for 28 day or in hospital mortality in patients with shock in which sepsis was the 
predominant etiology.[8] However, by utilizing the entire cohort of the large trial by De Backer 
and colleagues (1656 patients) rather than the 1044 who actually had septic shock, they 
included 612 patients without septic shock.[3] This included a subset of 280 patients with 
cardiogenic shock in which subgroup analysis in the original trial had already shown a 
significant mortality benefit for norepinephrine. The net effect would be to drown out the effect of 
the other five septic shock trials (only 364 patients in total). Hence, the effect estimates from this 
meta-analysis are unlikely to be reliable for the stated cohort of septic shock patients. In 
contrast, Havel et al. found insufficient evidence for superiority of one vasopressor over another 
among a series of pairwise analyses in their Cochrane review.[7] Correction for an error in the 
mortality figures extracted for one trial (Mathur et al.) does not change the non-significance of 
the original results for dopamine versus norepinephrine.[27] 
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The only network meta-analysis performed on this topic concluded with support for 
norepinephrine (with or without low dose vasopressin) as first line therapy for septic shock but 
suggested no strong evidence for epinephrine over dopamine as second line.[15] Statistical 
methods between our study and analysis were similar and so the differences in effect estimates 
once again likely relate to our selection of only trials reporting 28 day mortality and our inclusion 
of a trial missed in the search by Oba et al.[15] 
 
Strengths and limitations 
There were several strengths to this analysis. First, we performed a very broad and sensitive 
search of the major databases with no restriction on language (reflected in the large number of 
abstracts and titles screened). Second, by limiting to only those trials in which 28 day mortality 
was reported, we were afforded a greater deal of homogeneity in our comparisons for this 
outcome. Third, the network meta-analysis approach allowed us to explore comparative effects 
between the vasopressors taking into account both direct (pairwise) and indirect information. 
Finally, we also assessed the safety outcome of arrhythmia incidence which was not assessed 
in the only other published network meta-analysis of vasopressors in septic shock.[15] 
 
However, our study conclusions should also be borne in light of several limitations. First, our 
decision to exclude trials not reporting 28 day mortality may have affected the presented effect 
estimates and their statistical significance leading to a possible type two error. It should be 
noted that of the trials excluded on this basis, none were large trials (defined as greater than 
100 patients) or low risk of bias trials. A second limitation was that we were only able to assess 
mortality and arrhythmia incidence as our outcomes. Despite death being a fixed, objective and 
clinically relevant outcome, it is well recognised that mortality assessment does not capture all 
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of the clinical information relevant to patients and providers.[28] For example, adverse events, 
quality of life, duration of organ support and intensive care unit length of stay are commonly also 
of interest. However, the lack of reported data in these outcome domains meant that it would be 
unlikely that such a network meta-analysis would provide fruitful information. This was 
exemplified by the extremely large confidence intervals in our analysis of arrhythmias. Third, we 
feel that there was still extensive clinical heterogeneity in trials that were included (though there 
was no clear statistical evidence of this). Numerous variations in protocols and methods 
between studies included differences in drug timing, dosage, co-intervention, patient cohort and 
reporting quality of trials. There has been much literature on the heterogeneous nature of 
intensive care patients and the difficulties of performing research in this setting. It may be that 
certain subgroups of patients experience significant benefit when given specific vasopressors. 
We elected not to perform standard meta-regression analyses as many of the factors that we 
hypothesised could have led to such heterogeneity were not clearly reported. Finally, the small 
numbers of trials in each pairwise analysis precluded assessment of publication bias. 
 
Implications 
Our findings suggest that vasopressin is superior to dopamine in terms of 28 day mortality for 
septic shock. The comparisons for vasopressin versus norepinephrine and dopamine versus 
norepinephrine were not statistically significant. There was insufficient evidence to suggest a 
superior arrhythmia profile of one agent over another in the network meta-analysis though 
pairwise analysis confirmed the existing paradigm of dopamine leading to more arrhythmias 
than norepinephrine.  
 
Ongoing trials assessing specific contexts and cohorts are likely to shed further light on this 
topic. For example, the VANISH trial is assessing whether vasopressin, and its interaction with 
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steroids, is more effective at reducing kidney dysfunction while VANCS II is specifically 
investigating a cohort of cancer patients.[29,30] Finally, our findings suggest that care should be 
taken when interpreting the findings of nominally significant pairwise meta-analyses. The 
statistical significance of comparisons in such reviews can be greatly affected by a few small 
trials in such cases despite their small weight within the Forest plot.  
 
Conclusions 
In this network meta-analysis, vasopressin was superior to dopamine for 28 day mortality in 
septic shock. Existing pairwise information supports the use of norepinephrine over dopamine. 
Our findings suggest that dopamine should be avoided in patients with septic shock and that 
other vasopressor agents should continue to be based on existing guidelines and clinical 
judgement of the specific presentation and circumstances of the patient.   
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TABLES 
 
 
Table 1. Characteristics of included trials. 
 
 
Study and year 
No. of 
patients 
Intervention 
in group 1 
Intervention in 
group 2 Age 
Female 
(%) 
Severity 
score 
system 
Baseline 
severity 
score Therapy duration 
         Annane 2007 330 EPI NOREPI + DOB 63 39 SAPS II 53 As required to day 28 
De Backer 2010 1044 DOPA NOREPI NR NR NR NR As required to day 28 
Lauzier 2006 23 VASO NOREPI 54 39 APACHE II 23 Up to 48 hours 
Mahmoud 2012 60 NOREPI + DOB NOREPI + EPI 51 48 SOFA 15 NR 
Morelli 2008 32 NOREPI PHENYL 70 34 SAPS II 56 Up to 12 hours 
Morelli 2009 45 NOREPI VASO / TERLI 66 27 SAPS II 60 Up to 48 hours 
Myburgh 2008 158 EPI NOREPI NR NR NR NR Until target MAP without vasopressor 
Oliveira 2014 407 NOREPI VASO NR NR NR NR NR 
Patel 2002 24 NOREPI VASO 68 25 APACHE II 23 Up to 4 hours 
Patel 2010 252 DOPA NOREPI NR 54 APACHE II 28 As required to day 28 
Russell 2008 802 NOREPI VASO 61 38 APACHE II 27 As required 
Svoboda 2012 32 TERLI NOREPI 73 38 SOFA 18 Up to 72 hours 
Zambolim 2014 107 VASO NOREPI NR NR NR NR NR 
 
 
Abbreviations: APACHE, acute physiology and chronic health evaluation; DOB, dobutamine; DOPA, dopamine; EPI, epinephrine; 
MAP, mean arterial pressure; NOREPI, norepinephrine; NR, not reported; PHENYL, phenylephrine; SAPS, simplified acute 
physiology score; SOFA, sequential organ failure assessment; TERLI, terlipressin; VASO, vasopressin.
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Table 2. Risk of bias in included trials. 
 
 
Study and year 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
patients and 
healthcare 
providers 
Blinding of 
outcome 
assessors 
Missing 
outcome 
data 
Selective 
outcome 
reporting 
Source of 
funding 
        Annane 2007 Low Low Low Low Low Low Low 
De Backer 2010 Low Low Low Low Low Low Unclear 
Lauzier 2006 Low Low High High High Unclear Low 
Mahmoud 2012 Low Low Unclear Low Low Unclear Low 
Morelli 2008 Low Low Low Low Unclear Low Low 
Morelli 2009 Low Low Low Low Unclear Low Low 
Myburgh 2008 Low Low Low Unclear High Unclear Low 
Oliveira 2014 Unclear Unclear Unclear Unclear High Unclear Unclear 
Patel 2002 Low Unclear Unclear Unclear Unclear Unclear Unclear 
Patel 2010 High High High High Low Low Low 
Russell 2008 Low Low Low Low High Low Low 
Svoboda 2012 Low Low Unclear Unclear High Unclear Low 
Zambolim 2014 Unclear Unclear Unclear Unclear High Unclear Unclear 
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Table 3. 28 day mortality effect estimates from network meta-analysis. 
 
 
 
 
Norepinephrine Dopamine Epinephrine Vasopressins 
Norepinephrine 
& Epinephrine 
Norepinephrine 
& Dobutamine 
Norepinephrine - 
OR 1.2; 95% CI 
0.97 to 1.5 
OR 0.69; 95% 
CI 0.34 to 1.42 
OR 0.82; 95% 
CI 0.66 to 1.03 
OR 0.63; 95% 
CI 0.17 to 2.37 
OR 0.55; 95% 
CI 0.23 to 1.27 
Dopamine - - 
OR 0.58; 95% 
CI 0.27 to 1.22 
OR 0.68; 95% 
CI 0.5 to 0.94 
OR 0.52; 95% 
CI 0.14 to 2 
OR 0.45; 95% 
CI 0.19 to 1.09 
Epinephrine - - - 
OR 1.19; 95% 
CI 0.56 to 2.52 
OR 0.91; 95% 
CI 0.2 to 4.1 
OR 0.79; 95% 
CI 0.26 to 2.39 
Vasopressins - - - - 
OR 0.76; 95% 
CI 0.2 to 2.93 
OR 0.66; 95% 
CI 0.28 to 1.59 
Norepinephrine 
& Epinephrine - - - - - 
OR 0.87; 95% 
CI 0.18 to 4.21 
Norepinephrine 
& Dobutamine - - - - - - 
 
 
The odds ratio represents the odds of mortality in the agent at the top of the table relative to the agent in the first column of the 
table. Abbreviations: CI, 95% credible intervals (equivalent to 95% confidence intervals); OR, odds ratio.  
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Table 4. Arrhythmia effect estimates from network meta-analysis. 
 
 
 
 
Norepinephrine Dopamine Vasopressins Phenylephrine 
Norepinephrine - 
OR 3.32; 95% 
CI 0.15 to 75.73 
OR 0.4; 95% CI 
0.01 to 11.45 
OR 2.87; 95% CI 
0.01 to 584.92 
Dopamine - - 
OR 0.12; 95% CI 
0 to 11.79 
OR 0.86; 95% CI 
0 to 412.14 
Vasopressins - - - 
OR 7.18; 95% CI 
0.01 to 3863.37 
Phenylephrine - - - - 
 
 
The odds ratio represents the odds of arrhythmia incidence in the agent at the top of the table relative to the agent in the first 
column of the table. Abbreviations: CI, 95% credible intervals (equivalent to 95% confidence intervals); OR, odds ratio. 
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FIGURES 
 
 
Figure 1. Flow of records through the study selection process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of records identified through 
database searching 
5854 
Number of records screened 
4715 
Number of duplicates removed 
1139 
 
Number of titles and abstracts 
excluded 
4662 
 
Number of full-text records screened 
53 
Number of studies excluded 
40 
  
No assessment of 28 day mortality or 
arrhythmias (14), duplicate data (8), 
abstract irretrievable (8), non-
randomised (5), no separate data on 
septic shock (1), different doses of 
same drug (1), unclear treatment (1), 
full-text irretrievable (1), unconnected 
to treatment network (1) 
 
Final number of full-text studies 
included in analysis 
13
